Abstract | PURPOSE: EXPERIMENTAL DESIGN: RESULTS: uPA but not PAI-1 levels were consistently associated with malignant progression, with levels increased from low malignant potential tumors to primary tumors (uPA, P = 0.04; PAI-1, P = 0.019), from early to advanced disease stages (uPA, P = 0.014; PAI-1, P = 0.23), and from primary to intra-abdominal metastatic tumors (uPA, P = 0.001; PAI-1, P = 0.16). High uPA and PAI-1 levels were associated with residual tumor volumes of >1 cm (P = 0.001 and P = 0.016, respectively). Among invasive International Federation of Gynecologists and Obstetrician stages I-IV tumors, elevated levels of uPA (>5.5 ng/mg) and PAI-I (>18.8 ng/ml) were associated with a shortened progression-free survival (uPA, P = 0.003; PAI-1, P = 0.039) and overall survival (uPA, P = 0.0002; PAI-1, P = 0.007). In multivariate analysis, uPA retained prognostic independence for progression-free survival (P = 0.037) and overall survival (P = 0.006). CONCLUSIONS: These data suggest that the uPA/PAI-1 axis may play an important role in the intra-abdominal spread and reimplantation of ovarian cancer cells. The prognostic relevance of uPA and PAI-1 supports their possible role in the malignant progression of ovarian cancer.
|
Authors | G Konecny, M Untch, A Pihan, R Kimmig, M Gropp, P Stieber, H Hepp, D Slamon, M Pegram |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 7
Issue 6
Pg. 1743-9
(Jun 2001)
ISSN: 1078-0432 [Print] United States |
PMID | 11410515
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Plasminogen Activator Inhibitor 1
- Urokinase-Type Plasminogen Activator
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Disease Progression
- Disease-Free Survival
- Enzyme Activation
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Middle Aged
- Multivariate Analysis
- Ovarian Neoplasms
(diagnosis, metabolism, pathology)
- Plasminogen Activator Inhibitor 1
(biosynthesis)
- Prognosis
- Recurrence
- Time Factors
- Urokinase-Type Plasminogen Activator
(antagonists & inhibitors, biosynthesis)
|